Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives

详细信息    查看全文

• 作者：Carmen Criscitiello ; Fabrice André ; Alastair M Thompson…
• 刊名：Breast Cancer Research
• 出版年：2014
• 出版时间：April 2014
• 年：2014
• 卷：16
• 期：2
• 全文大小：199 KB
• 参考文献：1. Vignot, S, Besse, B, Andre, F, Spano, JP, Soria, JC (2012) Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. Crit Rev Oncol Hematol 84: pp. 301-313 CrossRef
  2. Amir, E, Clemons, M, Purdie, CA, Miller, N, Quinlan, P, Geddie, W, Coleman, RE, Freedman, OC, Jordan, LB, Thompson, AM (2012) Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 38: pp. 708-714 CrossRef
  3. Fisher, R, Pusztai, L, Swanton, C (2013) Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 108: pp. 479-485 CrossRef
  4. Amir, E, Miller, N, Geddie, W, Freedman, O, Kassam, F, Simmons, C, Oldfield, M, Dranitsaris, G, Tomlinson, G, Laupacis, A, Tannock, IF, Clemons, M (2012) Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 30: pp. 587-592 CrossRef
  5. Thompson, AM, Jordan, LB, Quinlan, P, Anderson, E, Skene, A, Dewar, JA, Purdie, CA (2010) Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the breast recurrence in tissues study (BRITS). Breast Cancer Res 12: pp. R92 CrossRef
  6. Aurilio, G, Monfardini, L, Rizzo, S, Sciandivasci, A, Preda, L, Bagnardi, V, Disalvatore, D, Pruneri, G, Munzone, E, Della Vigna, P, Renne, G, Bellomi, M, Curigliano, G, Goldhirsch, A, Nolè, F (2013) Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. Acta Oncol 52: pp. 1649-1656 CrossRef
  7. Lindstrom, LS, Karlsson, E, Wilking, UM, Johansson, U, Hartman, J, Lidbrink, EK, Hatschek, T, Skoog, L, Bergh, J (2012) Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 30: pp. 2601-2608 CrossRef
  8. Niikura, N, Liu, J, Hayashi, N, Mittendorf, EA, Gong, Y, Palla, SL, Tokuda, Y, Gonzalez-Angulo, AM, Hortobagyi, GN, Ueno, NT (2012) Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 30: pp. 593-599 CrossRef
  9. Curigliano, G, Bagnardi, V, Viale, G, Fumagalli, L, Rotmensz, N, Aurilio, G, Locatelli, M, Pruneri, G, Giudici, S, Bellomi, M, Della Vigna, P, Monfardini, L, Orsi, F, Nolè, F, Munzone, E, Goldhirsch, A (2011) Should liver metastases of breast cancer be biopsied to improve treatment choice?. Ann Oncol 22: pp. 2227-2233 CrossRef
  10. Gong, Y, Han, EY, Guo, M, Pusztai, L, Sneige, N (2011) Stability of estrogen receptor status in breast carcinoma: a comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy. Cancer 117: pp. 705-713 CrossRef
  11. Bogina, G, Bortesi, L, Marconi, M, Venturini, M, Lunardi, G, Coati, F, Massocco, A, Manfrin, E, Pegoraro, C, Zamboni, G (2011) Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Arch 459: pp. 1-10 CrossRef
  12. Wilking, U, Karlsson, E, Skoog, L, Hatschek, T, Lidbrink, E, Elmberger, G, Johansson, H, Lindstrom, L, Bergh, J (2011) HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat 125: pp. 553-561 CrossRef
  13. Aitken, S
• 刊物主题：Cancer Research; Oncology;
• 出版者：BioMed Central
• ISSN：1465-5411

文摘

Determination of hormone receptor (estrogen receptor and progesterone receptor) and human epidermal growth factor receptor 2 status in the primary tumor is clinically relevant to define breast cancer subtypes, clinical outcome, and the choice of therapy. Retrospective and prospective studies suggest that there is substantial discordance in receptor status between primary and recurrent breast cancer. Despite this evidence and current recommendations, the acquisition of tissue from metastatic deposits is not routine practice. As a consequence, therapeutic decisions for treatment in the metastatic setting are based on the features of the primary tumor. Reasons for this attitude include the invasiveness of the procedure and the unreliable outcome of biopsy, in particular for biopsies of lesions at complex visceral sites. Improvements in interventional radiology techniques mean that most metastatic sites are now accessible by minimally invasive methods, including surgery. In our opinion, since biopsies are diagnostic and changes in biological features between the primary and secondary tumors can occur, the routine biopsy of metastatic disease needs to be performed. In this review, we discuss the rationale for biopsy of suspected breast cancer metastases, review issues and caveats surrounding discordance of biomarker status between primary and metastatic tumors, and provide insights for deciding when to perform biopsy of suspected metastases and which one (s) to biopsy. We also speculate on the future translational implications for biopsy of suspected metastatic lesions in the context of clinical trials and the establishment of bio-banks of biopsy material taken from metastatic sites. We believe that such bio-banks will be important for exploring mechanisms of metastasis. In the future, advances in targeted therapy will depend on the availability of metastatic tissue.